SAMSUNG-ELECTRONICS
10.6.2021 10:02:29 CEST | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced the industry’s first 0.64-micrometer (μm)-pixel image sensor, the 50-megapixel (Mp) Samsung ISOCELL JN1. Equipped with the latest pixel technologies such as enhanced ISOCELL 2.0, Smart-ISO and Double Super PDAF, the JN1 can capture more vivid images on the industry’s smallest 50Mp mobile sensor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210610005350/en/
“Samsung’s advanced pixel technologies have once again pushed boundaries with the utmost precision to develop an image sensor with the industry’s smallest pixel size, yet with powerful performance. The new ISOCELL JN1 at 0.64μm will be able to equip tomorrow’s sleekest smartphones with ultra-high resolution mobile photographs,” said Duckhyun Chang, executive vice president of the sensor business at Samsung Electronics. “As we drive our commitment to innovation in pixel technologies, we will continue to bring a wide range of mobile image sensor offerings to the market.”
A new addition to Samsung’s high-resolution image sensor lineup, the JN1 employs ISOCELL 2.0 technology with added enhancements that improve light sensitivity by around 16-percent. For low-light environments, the sensor utilizes Samsung’s four-to-one pixel binning technology, Tetrapixel, which merges four adjacent 0.64μm-pixels into one big 1.28μm-pixel to quadruple light sensitivity for brighter 12.5Mp photographs.
With such advanced technologies all embedded in a small 1/2.76-inch optical format, the ISOCELL JN1 is the most versatile image sensor yet from Samsung. Through close collaboration with ecosystem partners, the JN1 is compatible with existing 1/2.8-inch products, allowing the sensor to be used for front-facing, ultra-wide or telephoto cameras, in addition to standard wide camera options. This means that users can take highly detailed selfies or group pictures in an amazing 50Mp resolution, as well as high-resolution video at up to 4K and high-zoom ratios. The smaller sensor can also reduce the height of the camera module by around 10-percent, minimizing the camera bulge for slimmer and more streamlined designs in next-generation smartphones.
For enhanced dynamic range, the ISOCELL JN1 comes with Smart-ISO, a technology that changes the conversion gain based on the environment’s illumination level. Smart-ISO uses Low ISO mode in bright settings to retain detail in the highlights, and High ISO in low-lit environments to reduce readout noise and generate excellent low-light performance. Using Smart-ISO, the JN1 also offers inter-scene HDR in mixed-light settings for optimum exposure levels derived from two separate readouts, from Low and High ISOs, that are merged to create a final image.
For faster auto-focus, the ISOCELL JN1 integrates improved Double Super PD. The previous Super PD technology used specially designed oval-shaped micro-lenses over two adjacent pixels arranged side by side to detect phases. Double Super PD features twice the density of pixels (1/16) used for phase detection than Super PD (1/32), enabling the same auto-focus performance even in environments with about 60-percent less illumination levels. For smooth crystal-clear videos, the image sensor supports up to 4K resolution video recording at 60 frames-per-second (fps) or full HD at 240fps.
The Samsung ISOCELL JN1 is currently in mass production.
* Editor's Note: Actual performance may vary depending on device and user environment.
* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0um-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. Samsung continues to enhance its pixel isolation methods with ISOCELL Plus and the ISOCELL 2.0 technologies.
###
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005350/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom